- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6428
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer ; volume:3 ; number:4 ; day:23 ; month:10 ; year:2017 ; pages:230-235 ; date:12.2017
Current molecular biology reports ; 3, Heft 4 (23.10.2017), 230-235, 12.2017
- Classification
-
Medizin, Gesundheit
- Creator
-
Culig, Zoran
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40610-017-0079-1
- URN
-
urn:nbn:de:1111-201801245824
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Culig, Zoran
- SpringerLink (Online service)
Other Objects (12)
Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators
Targeting molecular resistance in castration-resistant prostate cancer
Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators
Targeting molecular resistance in castration-resistant prostate cancer
Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators